STEMPOINT CAPITAL LP — 13F Holdings & Portfolio
CIK 1952142 · latest 13F-HR filed 2026-08-14
STEMPOINT CAPITAL LP manages $580.5M in 13F-reported U.S. long-equity assets across 85 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TNGX (6.59%), ABVX (6.51%), RVMD (5.16%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 25 new positions and exited 22; 26 existing positions rose in reported value and 21 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 41.2%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 30, 2026.
19TH FLOOR
NEW YORK, NY 10022
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| GORYNSKI, ROBERT, PETER Control | CHIEF FINANCIAL OFFICER since Aug 2023 | Less than 5% | Individual |
| ROAN, KEVIN, PATRICK Control | CHIEF COMPLIANCE OFFICER since Jan 2025 | Less than 5% | Individual |
| ROSS, MICHELLE, AVRA Control | CHIEF INVESTMENT OFFICER AND MANAGING PARTNER since Sep 2022 | 75% or more | Individual |
| STEMPOINT CAPITAL MANAGEMENT GP LLC Control | GENERAL PARTNER since Sep 2022 | Less than 5% | Domestic Entity |
| TAN, SEAN, CHUA Control | PRESIDENT AND MANAGING PARTNER since Sep 2022 | 25–50% | Individual |
| ROSS, MICHELLE, AVRA Control Indirect owner via STEMPOINT CAPITAL MANAGEMENT GP LLC | MANAGING MEMBER since Sep 2022 | 75% or more | Individual |
Ownership & leadership changes · 3 filings with changes since Nov 15, 2022
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedROAN, KEVIN, PATRICK · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedTAN, SEAN, CHUA · title CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, AND MANAGING PARTNER → PRESIDENT AND MANAGING PARTNER
- ChangedGORYNSKI, ROBERT, PETER · title CFO → CHIEF FINANCIAL OFFICER
- ChangedROSS, MICHELLE, AVRA · title CIO & MANAGING PARTNER → CHIEF INVESTMENT OFFICER AND MANAGING PARTNER
- ChangedROSS, MICHELLE, AVRA · indirect via STEMPOINT CAPITAL MANAGEMENT GP LLC: title CIO & MANAGING PARTNER → MANAGING MEMBER
- ChangedSTEMPOINT CAPITAL MANAGEMENT GP LLC · title GP OF THE IM → GENERAL PARTNER
- ChangedTAN, SEAN, CHUA · title CCO, COO AND MANAGING PARTNER → CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, AND MANAGING PARTNER
- AddedGORYNSKI, ROBERT, PETER · CFO · Less than 5% · control person
- ListedROSS, MICHELLE, AVRA · CIO & MANAGING PARTNER · 75% or more · control person
- ListedROSS, MICHELLE, AVRA · CIO & MANAGING PARTNER · 75% or more · indirect via STEMPOINT CAPITAL MANAGEMENT GP LLC · control person
- ListedSTEMPOINT CAPITAL MANAGEMENT GP LLC · GP OF THE IM · Less than 5% · control person
- ListedTAN, SEAN, CHUA · CCO, COO AND MANAGING PARTNER · 25–50% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- TANGO THERAPEUTICS INC$34.0M +809.6%
- ERASCA INC$24.8M +639.2%
- TYRA BIOSCIENCES INC$12.8M +173.2%
- DIANTHUS THERAPEUTICS INC$12.4M +172.9%
- ALKERMES PLC$10.1M +356.6%
Top Trims
- SCHOLAR ROCK HLDG CORP-$37.8M -74.2%
- IMMUNOVANT INC-$7.9M -42.5%
- STRUCTURE THERAPEUTICS INC-$7.6M -78.8%
- ARCUTIS BIOTHERAPEUTICS INC-$7.2M -73.4%
- PRAXIS PRECISION MEDICINES I-$5.7M -31.2%
New Positions
- KINIKSA PHARMACEUTICALS INTL$13.4M
- FIRST TRACKS BIOTHERAPEUTICS$12.5M
- ORUKA THERAPEUTICS INC$11.1M
- CLIMB BIO INC$9.7M
- INFLARX NV$7.2M
Exited Positions
- SYNDAX PHARMACEUTICALS INC$28.4M
- MBX BIOSCIENCES INC$14.9M
- DYNE THERAPEUTICS INC$9.2M
- EDGEWISE THERAPEUTICS INC$9.2M
- DENALI THERAPEUTICS INC$8.2M
STEMPOINT CAPITAL LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $38.2M | 6.59% | 1,223,019 | SH |
| 2 | ABIVAX SA | ABVX | 00370M103 | $37.8M | 6.51% | 283,657 | SH |
| 3 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $30.0M | 5.16% | 159,943 | SH |
| 4 | ERASCA INC | ERAS | 29479A108 | $28.7M | 4.94% | 1,565,913 | SH |
| 5 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $20.2M | 3.48% | 632,754 | SH |
| 6 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $19.6M | 3.37% | 200,851 | SH |
| 7 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $17.6M | 3.03% | 346,914 | SH |
| 8 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $16.3M | 2.80% | 602,686 | SH |
| 9 | BIOHAVEN LTD | BHVN | G1110E107 | $15.8M | 2.73% | 1,064,200 | SH |
| 10 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $13.4M | 2.30% | 209,234 | SH |
| 11 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $13.2M | 2.27% | 239,146 | SH |
| 12 | ALKERMES PLC | ALKS | G01767105 | $13.0M | 2.24% | 248,015 | SH |
| 13 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $12.5M | 2.16% | 622,723 | SH |
| 14 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $12.5M | 2.15% | 37,243 | SH |
| 15 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $12.3M | 2.12% | 348,408 | SH |
| 16 | BIOAGE LABS INC | BIOA | 09077V100 | $11.4M | 1.96% | 464,171 | SH |
| 17 | CG ONCOLOGY INC | CGON | 156944100 | $11.3M | 1.95% | 159,349 | SH |
| 18 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $11.1M | 1.91% | 116,461 | SH |
| 19 | IMMUNOVANT INC | IMVT | 45258J102 | $10.7M | 1.84% | 276,527 | SH |
| 20 | CELCUITY INC | CELC | 15102K100 | $10.3M | 1.77% | 98,203 | SH |
| 21 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $10.1M | 1.74% | 1,460,093 | SH |
| 22 | CLIMB BIO INC | CLYM | 28658R106 | $9.7M | 1.67% | 742,745 | SH |
| 23 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $9.5M | 1.64% | 106,926 | SH |
| 24 | ZURA BIO LTD | ZURA | G9TY5A101 | $8.1M | 1.39% | 1,368,215 | SH |
| 25 | INFLARX NV | IFRX | N44821101 | $7.2M | 1.25% | 3,228,255 | SH |
| 26 | SURROZEN INC | SRZN | 86889P208 | $7.1M | 1.22% | 273,140 | SH |
| 27 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $6.9M | 1.19% | 384,304 | SH |
| 28 | SURROZEN INC | SRZN | 86889P208 | $6.7M | 1.15% | 329,658 | SH |
| 29 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $6.6M | 1.14% | 178,412 | SH |
| 30 | OVID THERAPEUTICS INC | OVID | 690469101 | $6.5M | 1.12% | 2,417,283 | SH |
| 31 | EQUILLIUM INC | EQ | 29446K106 | $6.5M | 1.11% | 2,016,607 | SH |
| 32 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $6.5M | 1.11% | 137,124 | SH |
| 33 | CYTOKINETICS INC | CYTK | 23282W605 | $6.4M | 1.11% | 75,603 | SH |
| 34 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $5.6M | 0.97% | 216,194 | SH |
| 35 | INVENTIVA SA | IVA | 46124U107 | $5.4M | 0.93% | 1,426,320 | SH |
| 36 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $5.3M | 0.91% | 2,146,182 | SH |
| 37 | AURA BIOSCIENCES INC | AURA | 05153U107 | $5.1M | 0.87% | 714,280 | SH |
| 38 | EYEPOINT INC | EYPT | 30233G209 | $4.8M | 0.83% | 338,471 | SH |
| 39 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $4.7M | 0.81% | 170,378 | SH |
| 40 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $4.7M | 0.81% | 1,021,037 | SH |
| 41 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $4.6M | 0.79% | 76,075 | SH |
| 42 | UNIQURE NV | QURE | N90064101 | $4.1M | 0.70% | 88,115 | SH |
| 43 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $4.0M | 0.69% | 284,769 | SH |
| 44 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $3.9M | 0.67% | 118,000 | SH |
| 45 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $3.8M | 0.66% | 106,906 | SH |
| 46 | ALUMIS INC | ALMS | 022307102 | $3.8M | 0.66% | 135,736 | SH |
| 47 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $3.8M | 0.65% | 15,375 | SH |
| 48 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $3.7M | 0.64% | 153,544 | SH |
| 49 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $3.6M | 0.62% | 143,167 | SH |
| 50 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $3.6M | 0.62% | 358,780 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $580.5M | 85 | 0001420506-26-001687 |
| 2026-03-31 | 2026-05-15 | $514.6M | 83 | 0001420506-26-001107 |
| 2026-03-31 | 2026-05-18 | $522.3M | 84 | 0001420506-26-001177 |
| 2025-12-31 | 2026-02-17 | $583.2M | 78 | 0001420506-26-000490 |
| 2025-09-30 | 2025-11-14 | $499.1M | 90 | 0001420506-25-003308 |
19TH FLOOR
NEW YORK, NY 10022